145 related articles for article (PubMed ID: 37391168)
1. Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance.
Younes S; Zhao S; Bharadwaj S; Mosquera AP; Libert D; Johnsrud A; Majzner RG; Miklos DB; Frank MJ; Natkunam Y
Mod Pathol; 2023 Oct; 36(10):100256. PubMed ID: 37391168
[TBL] [Abstract][Full Text] [Related]
2. CD58 alterations govern antitumor immune responses by inducing PD-L1 and IDO in diffuse large B-cell lymphoma.
Xu X; Zhang Y; Lu Y; Zhang X; Zhao C; Wang J; Guan Q; Feng Y; Gao M; Yu J; Song Z; Liu X; Golchehre Z; Li L; Ren W; Pan-Hammarström Q; Zhang H; Wang X
Cancer Res; 2024 Apr; ():. PubMed ID: 38635903
[TBL] [Abstract][Full Text] [Related]
3. CD2-negative lymphoma-associated T-cells: a potential mechanism of immune-evasion in diffuse large B-cell lymphoma.
Ghosh A; Marques-Piubelli ML; Wang X; Sheu TG; Cheng J; Khan K; Lu W; Manning J; Tang G; Solis LM; Vega F
Virchows Arch; 2022 Oct; 481(4):659-663. PubMed ID: 35622145
[TBL] [Abstract][Full Text] [Related]
4. CD58 Immunobiology at a Glance.
Zhang Y; Liu Q; Yang S; Liao Q
Front Immunol; 2021; 12():705260. PubMed ID: 34168659
[TBL] [Abstract][Full Text] [Related]
5. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas.
Otsuka Y; Nishikori M; Arima H; Izumi K; Kitawaki T; Hishizawa M; Takaori-Kondo A
Mol Immunol; 2020 Mar; 119():35-45. PubMed ID: 31962268
[TBL] [Abstract][Full Text] [Related]
6. CD58 loss in tumor cells confers functional impairment of CAR T cells.
Yan X; Chen D; Ma X; Wang Y; Guo Y; Wei J; Tong C; Zhu Q; Lu Y; Yu Y; Wu Z; Han W
Blood Adv; 2022 Nov; 6(22):5844-5856. PubMed ID: 35728062
[TBL] [Abstract][Full Text] [Related]
7. Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses.
Romain G; Strati P; Rezvan A; Fathi M; Bandey IN; Adolacion JRT; Heeke D; Liadi I; Marques-Piubelli ML; Solis LM; Mahendra A; Vega F; Cooper LJ; Singh H; Mattie M; Bot A; Neelapu SS; Varadarajan N
J Clin Invest; 2022 Sep; 132(17):. PubMed ID: 35881486
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
9. [Research Progress on Relationship between CD58 Molecule and ALL and Lymphoma -Review].
Lu YJ; Qiu LL; Wang LL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):592-595. PubMed ID: 28446317
[TBL] [Abstract][Full Text] [Related]
10. Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features.
Maes B; Anastasopoulou A; Kluin-Nelemans JC; Teodorovic I; Achten R; Carbone A; De Wolf-Peeters C;
Ann Oncol; 2001 Jun; 12(6):853-8. PubMed ID: 11484964
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with
Luchtel RA; Dasari S; Oishi N; Pedersen MB; Hu G; Rech KL; Ketterling RP; Sidhu J; Wang X; Katoh R; Dogan A; Kip NS; Cunningham JM; Sun Z; Baheti S; Porcher JC; Said JW; Jiang L; Hamilton-Dutoit SJ; Møller MB; Nørgaard P; Bennani NN; Chng WJ; Huang G; Link BK; Facchetti F; Cerhan JR; d'Amore F; Ansell SM; Feldman AL
Blood; 2018 Sep; 132(13):1386-1398. PubMed ID: 30093402
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
13. CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse.
Abdul Razak FR; Diepstra A; Visser L; van den Berg A
Genes Immun; 2016 Sep; 17(6):363-6. PubMed ID: 27467287
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
[TBL] [Abstract][Full Text] [Related]
15. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
16. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
18. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
[TBL] [Abstract][Full Text] [Related]
19. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
20. Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
Jeyakumar N; Smith M
Front Immunol; 2022; 13():887866. PubMed ID: 35663947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
